38 commercial payer policies list J2323. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
38 policies from 19 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri)Effective 01/01/2019 - 05/31/2019 | Jan 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab (Tysabri)Effective 02/01/2023 - 05/31/2023 | Feb 1, 2023 | Prior auth requiredInferred from policy title |
| Natalizumab (Tysabri)Effective 03/01/2022 - 01/31/2023 | Mar 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Natalizumab (Tysabri)Effective 04/01/2021 - 02/28/2022 | Apr 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Natalizumab (Tysabri)Effective 05/01/2020 - 03/31/2021 | May 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Natalizumab (Tysabri)Effective 06/01/2023 - 04/30/2024 | Jun 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Natalizumab (Tysabri)Effective 07/01/2019 - 04/30/2020 | Jul 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Natalizumab Products (Tysabri, Tyruko) | Feb 1, 2026 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Tysabri (natalizumab) InjectionEffective 05/01/2024 - 04/30/2025 | May 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Tysabri (natalizumab) InjectionEffective 05/01/2025 - 01/31/2026 | May 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tyruko & Tysabri) | Jul 1, 2026 | Covered |
| Natalizumab (Tyruko & Tysabri) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab (Tyruko & Tysabri) – Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri) and Related Biosimilars | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab (Tysabri) and Related Biosimilars | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab and Associated Biosimilar(s) | May 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab and Associated Biosimilar(s) | May 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab and Associated Biosimilar(s) | May 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab and Associated Biosimilar(s) | May 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab Tysabri 2 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab Tysabri ME | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri, Tyruko) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab (Tysabri, Tyruko) - Minnesota Health Care Programs | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri) and Related Biosimilars | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Natalizumab (Tysabri) and Related Biosimilars | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (e.g., Tysabri) and Biosimilars | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri), Natalizumab-sztn (Tyruko) | Jan 13, 2007 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri) Natalizumab-sztn (Tyruko); CP.PHAR.259 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tysabri) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab: (Tysabri; Tyruko) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab and Natalizumab Biosimilars (Tysabri, Tyruko) (PG195, Ver. 6) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tyruko & Tysabri) | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J2323 |
|---|---|---|
| Natalizumab (Tyruko & Tysabri) | Jul 1, 2026 | Covered |